Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
Results from the 2002-03 Palivizumab Outcomes Registry: focus on congenital airway abnormalities & neuromuscular disease. 2004 Pediatric Academic Societies Meeting